Robeco Institutional Asset Management B.V. Acquires 168,153 Shares of Stryker Corporation (NYSE:SYK)

Robeco Institutional Asset Management B.V. raised its stake in Stryker Corporation (NYSE:SYK) by 109.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 321,247 shares of the medical technology company’s stock after acquiring an additional 168,153 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.08% of Stryker worth $119,584,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in SYK. Sequoia Financial Advisors LLC lifted its stake in Stryker by 2.6% in the 1st quarter. Sequoia Financial Advisors LLC now owns 12,390 shares of the medical technology company’s stock valued at $4,612,000 after purchasing an additional 316 shares during the last quarter. Terra Nova Asset Management LLC increased its holdings in shares of Stryker by 0.7% during the first quarter. Terra Nova Asset Management LLC now owns 8,399 shares of the medical technology company’s stock worth $3,127,000 after buying an additional 55 shares in the last quarter. Pure Financial Advisors LLC lifted its stake in shares of Stryker by 106.4% in the 1st quarter. Pure Financial Advisors LLC now owns 2,178 shares of the medical technology company’s stock valued at $811,000 after acquiring an additional 1,123 shares during the last quarter. Security National Bank boosted its holdings in shares of Stryker by 2.6% during the 1st quarter. Security National Bank now owns 26,481 shares of the medical technology company’s stock valued at $9,858,000 after acquiring an additional 672 shares in the last quarter. Finally, Perigon Wealth Management LLC grew its position in Stryker by 3.2% during the 1st quarter. Perigon Wealth Management LLC now owns 4,209 shares of the medical technology company’s stock worth $1,567,000 after acquiring an additional 131 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Up 1.5%

Shares of NYSE SYK opened at $392.36 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.64 and a debt-to-equity ratio of 0.69. The firm has a market cap of $149.76 billion, a PE ratio of 53.02, a P/E/G ratio of 2.91 and a beta of 0.91. The company’s fifty day simple moving average is $377.18 and its 200 day simple moving average is $375.31. Stryker Corporation has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.50 earnings per share. As a group, sell-side analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker’s payout ratio is currently 45.41%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the subject of several recent research reports. Sanford C. Bernstein set a $450.00 price objective on Stryker in a research note on Monday, May 5th. Needham & Company LLC restated a “buy” rating and issued a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. Citigroup reiterated a “buy” rating and set a $455.00 price target (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Evercore ISI decreased their price objective on Stryker from $400.00 to $390.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Finally, Roth Mkm raised their target price on Stryker from $405.00 to $456.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $427.30.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.